phamax provides end-to-end pharmaceutical launch strategy consulting for organisations preparing for, executing or optimising launches across European and global markets.
OUR PRACTICE
In specialty care and rare disease, successful launches depend on market intelligence, real-world evidence, payer access expertise and commercial judgement. phamax connects these inputs into practical launch decisions that teams can use before, during and after launch.
Common challenges clients bring to us during launch
Client challenges
Launch teams rarely come with one isolated problem. They need clear answers across evidence, access, field execution, and leadership decision-making.
Are we aligned on the right
launch decisions?
Medical, market access and commercial teams often move with different assumptions. Bring the evidence, priorities and actions into one launch plan before execution begins.
Where is launch momentum
being lost?
Early signals are hard to read when sales, access, account, patient-pathway and field data sit apart. Connect them to spot where momentum is building, and where it is stalling.
Why does performance vary by market, region, or account?
Sales tells you what happened, not why. Separate structural barriers such as access, diagnostics or patient opportunity
from execution issues such as targeting, coverage and
account activation.
Where should we focus the next
investment or action?
The next planning cycle demands clear priorities. Identify the markets, regions, institutions or accounts where added focus is most likely to improve launch performance.
Launch advisory model
Three moments where launch teams need sharper decisions.
Stage 01 / Pre-Launch
3-4 years to launch
Prepare: define where to play before investment decisions harden.
Build the evidence base, patient opportunity view, and access strategy early enough to shape launch sequencing and commercial resource choices.
-
Opportunity sizing, patient segmentation and pathway mapping.
-
Payer value assessment, analog benchmarking and launch sequencing.
-
GTM design, customer segmentation and cross-functional alignment.
Stage 02 / Launch Monitoring
Go-live to month 6
Monitor: read early signals before they become launch patterns.
Create a measurement rhythm that shows whether uptake, access, account activation, and field activity are moving in the right direction.
-
KPI framework, reporting cadence and escalation thresholds.
-
Account activation, access milestone and field activity tracking.
-
Course-correction recommendations inside the planning cycle.
phamax supports the three points where launch decisions carry the highest commercial consequence: how to prepare, how to monitor, and where to act next.
Stage 03 / Post-Launch Diagnostic
0-12 months post-launch
Act: explain performance variance and prioritise what to do next.
Connect sales, patient opportunity, access, pathway, account, and field inputs to show why performance varies and where commercial focus should move.
-
Performance vs. opportunity analysis at regional and account level.
-
Patient pathway, diagnostic and institutional bottleneck identification.
-
Priority region, institution and account list with leadership recommendations.
Common challenges clients bring to us during launch
Client challenges
Launch teams rarely come with one isolated problem. They need clear answers across evidence, access, field execution, and leadership decision-making.
Client decision question
Start with the right commercial question: where to play, who to prioritise and how to act.
Evidence + data inputs
Assemble market research, epidemiology, access, sales, account, CRM and competitive evidence.
AI-supported synthesis
Accelerate pattern detection, signal finding, evidence structuring and cross-workstream synthesis.
Consultant challenge
Senior consultants challenge assumptions, add pharma context and pressure-test the findings.
Decision-ready recommendation
Convert the diagnosis into clear recommendations, next steps and a leadership presentation.
From fragmented launch inputs to decision-ready action.
Client challenges
Rare Disease
100+
projects across European markets since 2014
Haemophilia, lysosomal storage disorders, muscular dystrophy, hereditary angioedema, primary sclerosing cholangitis
Oncology
Deep oncology
experience
across six
indications
Breast, gastric, renal cell, hepatocellular, lung and pancreatic cancer
EU Market Depth
10+
European markets
covered
Germany, France, UK, Netherlands, Switzerland, Nordics and additional EU markets
Post-launch diagnostic case study
Rare-disease oncology. Germany. 200+ brick-level regions.
200+
regions analysed
4
diagnostic lenses
6 wks
to recommendation
A rare-disease oncology product launched across Germany. National reporting showed early traction but could not explain regional post-launch variance in uptake.
​
phamax connected sales, patient pathway data, access status and field activity across 200+ brick-level territories.
Output:Â a prioritised territory action plan that redirected commercial investment to the highest-potential areas within six weeks.
Launch Excellence Assessment
Know where your launch readiness is strongest — and where it is exposed.
Score A
Launch Ready
Full diagnostic scope. Discuss next steps with a launch expert.
Score B
Launch Developing
Focused diagnostic possible. Some data assembly may be needed.
10 questions. Five minutes. Receive a Launch Excellence score and a recommendation on whether your team is ready for a full diagnostic, a focused review, or a measurement foundation sprint.
Score C
Launch Foundation
Measurement foundation sprint
recommended first.
Insights & latest
Launch excellence insights and tools.
White Paper
The Evolution of Pharma Launch Excellence: 2000 to 2026
Legacy planning, the specialty care shift and how AI changes speed, depth and precision.
Register for early access
White Paper
Data-Driven Strategies for Rare Disease Launch Phases
Monthly insight series on EU launch dynamics and why the first six months matter.
Subscribe for updates
LIVE
Know where your launch readiness is strongest and where it is exposed.